Impact of increasing alanine aminotransferase levels within normal range on incident diabetes

Journal of the Formosan Medical Association

Volumn 111, Issue 4, 2012, Pages 201-208

  Wang, Chong Shan ^a,b   Chang, Ting Tsung ^c   Yao, Wei Jen ^c   Wang, Shan Tair ^d   Chou, Pesus ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b A Lein Community Health Center   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Alanine aminotransferase; Cohort study; Incident type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RISK; RISK ASSESSMENT; TAIWAN;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; REFERENCE VALUES; RISK FACTORS; SOCIOECONOMIC FACTORS; TAIWAN;

EID: 84862806948     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2011.04.004     Document Type: Article

References (28)

1. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Taylor R. Causation of type 2 diabetes-the Gordian knot unravels. N Engl J Med 2004, 350:639-641.
3. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., Ko S.H., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.
4. Schulze M.B., Hu F.B. Primary prevention of diabetes: what can be done and how much can be prevented?. Annu Rev Public Health 2005, 26:445-467.
5. Hu F.B., Meigs J.B., Li T.Y., Rifai N., Manson J.E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53:693-700.
6. Meigs J.B., Hu F.B., Rifai N., Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
7. Ioannou G.N., Weiss N.S., Boyko E.J., Kahn S.E., Lee S.P. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005, 128:627-635.
8. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-112.
9. Sattar N., Scherbakova O., Ford I., O'Reilly D.S., Stanley A., Forrest E., et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004, 53:2855-2860.
10. Vozarova B., Stefan N., Lindsay R.S., Saremi A., Pratley R.E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:1889-1895.
11. Wannamethee S.G., Shaper A.G., Lennon L., Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005, 28:2913-2918.
12. Hanley A.J., Williams K., Festa A., Wagenknecht L.E., D'Agostino R.B., Kempf J., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004, 53:2623-2632.
13. Ford E.S., Schulze M.B., Bergmann M.M., Thamer C., Joost H.G., Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 2008, 31:1138-1143.
14. Schindhelm R.K., Dekker J.M., Nijpels G., Heine R.J., Diamant M. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn study [letter]. Diabetes Care 2005, 28:2812.
15. Nannipieri M., Gonzales C., Baldi S., Posadas R., Williams K., Haffner S.M., et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005, 28:1757-1762.
16. Andre P., Balkau B., Born C., Royer B., Wilpart E., Charles M.A., et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study. Diabetes Metab 2005, 31:542-550.
17. Wang C.S., Chang T.T., Yao W.J., Wang S.T., Chou P. Comparison of HBV and HCV prevalence and risk factors in a community-based study. Am J Trop Med Hyg 2002, 66:389-393.
18. Wang C.S., Wang S.T., Yao W.J., Chang T.T., Chou P.H.C.V. Infection and the development of type 2 diabetes. Am J Epidemiol 2007, 166:196-203.
19. Whiting D., Unwin N., Roglic G. Diabetes: equity and social determinants. Equity, social determinants and public health programmes 2010, WHO Press, World Health Organization, Geneva, Switzerland, [accessed 16.03.11]. http://whqlibdoc.who.int/publications/2010/9789241563970_eng.pdf, E. Blas, A.S. Kurup (Eds.).
20. Ardigo D., Numeroso F., Valtuena S., Franzini L., Piatti P.M., Monti L., et al. Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transaminase concentrations. Metabolism 2005, 54:1566-1570.
21. Kim H.J., Kim H.J., Lee K.E., Kim D.J., Kim S.K., Ahn C.W., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004, 164:2169-2175.
22. Hanley A.J., Williams K., Festa A., Wagenknecht L.E., D'Agostino R.B., Haffner S.M., et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147.
23. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.H., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
24. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
25. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
26. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005, 43:1060-1066.
27. Ryan M.C., Abbasi F., Lamendola C., Carter S., McLaughlin T.L. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 2007, 30:1075-1080.
28. Tseng C.H., Tseng C.P., Chong C.K., Huang T.P., Song Y.M., Chou C.W., et al. Increasing incidence of diagnosed T2D in Taiwan: analysis of data from a national cohort. Diabetologia 2006, 49:1755-1760.